Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Owen

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Leukemia|February 27, 2024
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemiaRuth de Tute, Nicholas Counsell, Laura Clifton-Hadley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2011
Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skinMelvin Lee Kiang Chua, Navita Somaiah, Sara Bourne, et al.
The Science of the Total Environment|February 14, 2012
The European reference condition concept: A scientific and technical approach to identify minimally-impacted river ecosystemsIsabel Pardo, Carola Gómez-Rodríguez, Jean-Gabriel Wasson, et al.
British Journal of Haematology|May 8, 2014
Updates to the guidelines for the diagnosis and management of multiple myelomaGuy Pratt, Matthew Jenner, Roger Owen, et al.
British Journal of Haematology|January 30, 2013
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapyAnnamaria Brioli, Kevin D Boyd, Martin F Kaiser, et al.
British Journal of Cancer|July 21, 2017
Active multiple myeloma suppresses and typically eliminates coexisting MGUSJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 24, 2016
Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapyNavita Somaiah, Melvin L K Chua, Sara Bourne, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 8, 2021
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple MyelomaJessica Caro, David Cairns, Tom Menzies, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Leukemia|February 27, 2024
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemiaRuth de Tute, Nicholas Counsell, Laura Clifton-Hadley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2011
Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skinMelvin Lee Kiang Chua, Navita Somaiah, Sara Bourne, et al.
The Science of the Total Environment|February 14, 2012
The European reference condition concept: A scientific and technical approach to identify minimally-impacted river ecosystemsIsabel Pardo, Carola Gómez-Rodríguez, Jean-Gabriel Wasson, et al.
British Journal of Haematology|May 8, 2014
Updates to the guidelines for the diagnosis and management of multiple myelomaGuy Pratt, Matthew Jenner, Roger Owen, et al.
British Journal of Haematology|January 30, 2013
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapyAnnamaria Brioli, Kevin D Boyd, Martin F Kaiser, et al.
British Journal of Cancer|July 21, 2017
Active multiple myeloma suppresses and typically eliminates coexisting MGUSJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 24, 2016
Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapyNavita Somaiah, Melvin L K Chua, Sara Bourne, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 8, 2021
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple MyelomaJessica Caro, David Cairns, Tom Menzies, et al.
Pageof 8